Innovation and R&D are the keys to a healthier future

Written by Nathalie Moll on 7 April 2017 in Thought Leader
Thought Leader

Innovation and R&D are the keys to a healthier future, explains Nathalie Moll.

Nathalie Moll | Photo credit: EFPIA


Innovation, built on the foundation of solid research and development (R&D), is key to improving health outcomes. The value of healthcare R&D can be illustrated through the Innovative Medicines Initiative (IMI) - the world's largest public-private partnership in the life sciences sector.

While a company or institution would find it extremely difficult to individually address existing scientific knowledge gaps, IMI allows them to join forces with the public sector to explore Europe's major societal challenges. 

The sheer potential of IMI is reflected in its diverse array of projects, including - to mention only a few: Alzheimer's (ADAPTED/EPAD/AMYPAD); antimicrobial resistance (ND4BB/ COMBACTE/DRIVE-AB); Ebola (Ebola+); diabetes (DIRECT/IMIDIA/INNODIA); and animal welfare in research (STEMBANCC).


RELATED CONTENT


We are now witnessing the emergence of therapies that can: stimulate a patient's own immune system to combat cancer; use antibacterial monoclonal antibodies to target bacteria that are resistant to normal antibiotics; deliver medicines targeting autoimmune disorders; and produce advanced cell and gene therapies that can replace or repair faulty cells and even genes. 

Promoting access to these groundbreaking therapies is not without its challenges. Decision-makers and clinicians may have doubts over a new therapy's effectiveness, while novel therapies also may be disruptive to health systems due, for example, to issues such as high up-front costs or even the potential to cure rather than treat an illness. To resolve cost issues, we should look at 'managed entry agreements'.

These can be employed to peg the reimbursement of a therapy to a monitoring programme where data is collected continuously from patients that can confirm the long-term value of a treatment.

Replacing a lifetime supply of medicines with one, highly advanced and high-cost intervention at a single point in time may also pose challenges. Health policymakers and healthcare managers, together with industry, are keen to find new solutions where older ones are no longer fit for purpose. 

It is also fundamentally important to agree ways in which R&D can be supported. Bringing innovative medicines that are safe and efficient is a long, complex, risky and costly process that requires industry to invest billions of euros.

Existing pharmaceutical incentives have enabled the research and development of today's therapies and will lead to the cures of tomorrow. They are a fundamental ingredient to developing solutions to patients' unmet needs and represent the foundation on which basic science can be turned into new treatments.

Despite these challenges, there are many reasons to be optimistic about the future of healthcare in Europe. With over 7000 medicines in development, an exciting new wave of innovation is set to play a vital role in addressing future challenges. 

Realising this potential will require stakeholders to work together to foster an environment that supports the kind of innovation that can continue to transform the lives of patients.

 

About the author

Nathalie Moll is the Director General of EFPIA

Share this page

Tags

Categories

Partner content

This content is published by the Parliament Magazine on behalf of our partners.

Related Articles

Issue 465 | 20 November 2017
21 November 2017

Julian King interview, Cybersecurity, Press Freedom, Cohesion Policy,  Wildlife Trafficking, Rare Diseases, Workers' Rights, Open Innovation, Security of Energy supply, 5...

It's time to extend EU's digital transformation to health and care
13 November 2017

Digital technologies are a huge part of our daily lives, so it’s time to extend their scope into healthcare, writes Vytenis Andriukaitis.

eHealth: Innovation is the best policy plan
13 November 2017

Technology is transforming healthcare, and the EU must come up with the right regulatory framework to keep up, says Michał Boni.

Related Partner Content

PM+: Cosmetics animal testing ban under threat
19 May 2015

The EU must ensure that cosmetic ingredients made in Europe are never tested on animals, argues Dr Julia Baines of PETA.

Particulate matter pollution a major cause of air quality illnesses
10 October 2016

The EU must do more to tackle the problem of particulate matter (PM), argues Jaume Loffredo.